INVITATIONAL LECTURES AND SEMINARS

1. "The Role of Glycosaminoglycans in Experimental Amyloidosis", Dept. of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania, March 1986.

2. "Sulphated Glycosaminoglycans in Experimental Amyloidosis, Acute Inflammation and Alzheimer's Disease", Department of Pathology, University of Washington, May 1986.

3. "Characterization of Splenic and Plasma Glycosaminoglycans during Experimental Amyloidosis and Acute Inflammation", Department of Neurology, University of California, San Francisco, CA, May 1986.

4. "Why are Sulphated Glycosaminoglycans Always Found in Association with Amyloid Deposits?", Department of Orthopaedic Surgery, Tuft's University, Boston, MA, June 1986.

5. "Sulphated Glycosaminoglycans, A Common Constituent of All Amyloids Including Those Found in Alzheimer's, Kuru, Scrapie, Creutzfeldt-Jakob Disease and Gerstmann-Straussler Syndrome", Alzheimer's Disease Research Center, University of Washington, Seattle, WA, May 1987.

6. "Corpora Amylacea in Aging and Alzheimer's Brain Contains Antigenic Sites for Chondroitin Sulfate and Heparan Sulfate Proteoglycans", Vth International Symposium on Amyloidosis, Hakone, Japan, October 1987.

7. "The Possible Role of Proteoglycans in the Pathogenesis of Alzheimer's Disease and Other Amyloidoses", Department of Neurology, Harvard Medical School and Brigham & Women's Hospital, Boston, MA, December 1988.

8. "Proteoglycans in the Pathogenesis of Alzheimer's disease and Other Amyloidoses", American Health Assistance Foundation 15th Anniversary Symposium, Tuscon, Arizona, February 1989.

9. "The Possible Involvement of Specific Proteoglycans in the Pathogenesis of Alzheimer's Disease and Other Amyloidoses", The 13th International Symposium on Brain Sciences, La Jolla, CA, February 1990.

10. "Early Accumulation of Heparan Sulfate in Neurons and in the Beta-amyloid Protein Containing Lesions of Alzheimer's Disease and Down's Syndrome", The 2nd International Conference on Alzheimer's Disease and Related Disorders, Toronto, Canada, July 1990.

11. "Heparan Sulfate Accumulation in the Beta-amyloid Protein Containing Lesions of Alzheimer's Disease and Down's Syndrome is an Early Event", The 6th International Conference on Amyloidosis, Oslo, Norway, August 1990.

12. "Specific Proteoglycans in the Pathogenesis of Alzheimer's Disease", Alzheimer's Disease Center, University of Southern California, Los Angeles, CA, May 1991.

13. "Specific Proteoglycans in the Pathogenesis of Alzheimer's Disease", The 4th Annual Meeting of the Society for Experimental Neuropathology, Seattle, WA, September 1991.

14. "Specific Proteoglycans in the Pathogenesis of Alzheimer's Disease", Alzheimer's Disease Research Center, Case Western Reserve University, Cleveland, Ohio, October 1991.

15. "Specific Proteoglycans in the Pathogenesis of Alzheimer's Disease", The 14th Forum: Carbohydrates Coming of Age, Tokyo, Japan, May 1992.

16. "Specific Proteoglycans in the Pathogenesis of Alzheimer's Disease", Aichi Medical University, Nagoya, Japan, May 1992.

17. "Specific Proteoglycans in the Pathogenesis of Alzheimer's Disease", Glycomed Inc., Alameda, CA, October 1992

18. "Specific Proteoglycans in the Pathogenesis of Alzheimer's Disease", Seattle VA Medical Center, November 1992

19. "Specific Proteoglycans in the Pathogenesis of Alzheimer's Disease", Collaborative Biomedical Products, Bedford, MA, November 1992

20. "A Rat Model of ß/A4 Amyloid Deposition in Brain", University of Philadelphia Alzheimer's Disease Research Center, Philadelphia, PA, November 1992

21."In Vivo and In Vitro Models to Unravel the Role of ß/A4 in the Pathogenesis of Alzheimer's Disease", International Symposium on the Hippocampus, Frankfurt, Germany, December 1992.

22. "Specific Proteoglycans for the Development of an Animal Model of Alzheimer's Disease Amyloidosis", Dept. of Pathology, University of Washington, Seattle, February 1993.

23. "Heparan Sulfate Proteoglycans: Their Role in the Development of a New Reliable Animal Model of Alzheimer's Disease Amyloidosis", Cell Therapeutics Inc., Seattle, May 1993.

24. "Heparan Sulfate Proteoglycans: Their Role in the Development of a New Animal Model of Alzheimer's Disease Amyloidosis", Dept. of Neurological Surgery, University of Washington, Seattle, July 1993

25. "Beta-Amyloid and Associated Proteoglycans/Glycosaminoglycans: In Vitro and In Vivo Models", National Caregiving Foundation First Symposium, Palm Springs, CA, November 1993.

26. "Apolipoproteins and chaperons in Alzheimer's: promiscuous or innocent escorts?", 28th Annual Winter Conference on Brain Research, Steamboat Springs, Colorado, January 1995.

27. "Targeting Heparan Sulfate Proteoglycan-Amyloid Protein Interactions for the Treatment of Alzheimer's Disease and Other Amyloidoses", Dept. of Neurology, University of California, San Diego, CA, October 1995.

28. "Targeting Heparan Sulfate Proteoglycan Interactions for the Treatment of Alzheimer's disease and Other Amyloidoses", Center for Molecular Medicine and Therapeutics, University of British Columbia, Vancouver, Canada, November 1995.

29. “Specific Proteoglycans in the Pathogenesis of Alzheimer’s Disease and Other Amyloidoses”, Proteoglycan Gordon Conference, Proctor Academy, New Hampshire, July 1996.

30. “Specific Proteoglycans in the Pathogenesis of Alzheimer’s Disease and Other Amyloidoses”, Dept. of Orthopaedics, University of Washington, July 1996.

31. "Specific Proteoglycans in the Pathogenesis of Alzheimer's Disease and Other Amyloidoses", Astra Arcus, Rochester, New York, January 1997.

32. "Further Evidence Implicating Perlecan and Other Heparan Sulfate Proteoglycans in the Pathogenesis of Alzheimer's Disease and Other Amyloidoses", Joint meeting of the International Society for Neurochemistry and the American Society for Neurochemistry, Boston, MA, July 1997.

33. "Further Evidence Implicating Perlecan and Other Heparan Sulfate Proteoglycans in the Pathogenesis of Alzheimer's Disease and Other Amyloidoses", Suncoast Gerontology Center, University of South Florida, College of Medicine, Tampa, Fl, September 1997.

34. "Further Evidence Implicating Perlecan and Other Heparan Sulfate Proteoglycans in the Pathogenesis of Alzheimer's Disease and Other Amyloidoses", Dept. of Cell and Neurobiology, University of Southern California-Los Angeles, Los Angeles, CA, January 1998.

35. "Further Evidence Implicating Perlecan and Other Heparan Sulfate Proteoglycans in the Pathogenesis of Alzheimer's Disease and Other Amyloidoses", McClean Hospital and Harvard Medical School, Boston, MA, July 1998.

36. "Perlecan and Other Heparan Sulfate Proteoglycans in the Pathogenesis of Alzheimer's Disease", 15th National Meeting of the British Neuroscience Association. Harragate, England, April 1999.

37. "Perlecan and Other Heparan Sulfate Proteoglycans in the Pathogenesis of Alzheimer's Disease and Other Smyloidoses", Wenner-Gren Foundations International Symposium on "Heparan Sulfate Proteoglycans", Stockholm, Sweden, April 1999.

38. "PTI-00703 as a Natural Therapeutic for the Inhibition of Alzhiemer's Aß Fibrillogenesis", Alzheimer's Disease Cooperative Study Steering Committee Group, New Orleans, LO, January 2000.

39. "The Discovery of PTI-00703 and Related Natural Compounds Derived from the Amazon Rain Forest That are Effective Inhibitors of Alzheimer's Amyloid Fibrillogenesis", Oregon Heath Sciences University, Portland, OR, February 2001.

40. "ProteoTech Inc.", Company profile presentation at the 1st BioAsia Pacific Conference, Honululu, Hawaii, April 17-19, 2001.

41. "Proteoglycans/Glycosaminoglycans in the Induction of Alzheimer's Amyloid Plaque Formation and the Discovery of Natural Anti-amyloid Agents". IXth International Symposium on Amyloidosis, Budapest, Hungary, July 2001.

42. "ProteoTech Inc.", Company profile presentation at Invest Northwest, Seattle, WA, March 2002.

43. "ProteoTech Inc.", Company profile presentation at Invest Northwest, Seattle, WA, March 2003.

44. "Specific Proteoglycans/ Glycosaminoglycans in the Pathogenesis of Alzheimer's Disease and Related Disorders". Presentation at the Sixth International Conference on Alzheimer's disease and Parkinson's disease, Seville, Spain, May 2003.

45. “ProteoTech Inc.”, Company profile presentation at Invest Northwest, Seattle, WA, March 2004.

46. “Alzheimer’s Amyloid Plaque Formation Induced by Sulfated Glycosaminoglycans are Resistant to Degradation by Proteases and Microglia”. Presentation at the Xth International Symposium on Amyloid and Amyloidosis, Tours, France, April 2004.

47. “Development of Exebryl-1: A Disease Modifying Compound that Causes a Marked Clearance of Brain Amyloid Plaque Burden and Improved memory in Transgenic Mouse Models of Alzheimer’s disease”. Presentation at Alzheimer’s Disease:From Molecular Mechanisms to Drug Discovery, Cancun, Mexico, December 11-17, 2004.

48. “Proteoglycans/Glycosaminoglycans in the Pathogenesis of Alzheimer’s and Parkinson’s Disease and the Development of Novel Small Molecule Amyloid Disease-Modifying Therapeutics”. Presentation at the 8th International Conference on Alzheimer’s and Parkinson’s Disease, Saltzburg, Austria, March 2007.

49. “Novel Ways to Reduce Protein Aggregation.” 5th Drug Discovery for Neurodegeneration: An Intensive Course on Translating Research into Drugs. San Diego, CA, February 2011.